Interviews
KIMCo CEO talks to Scrip about how the Korean open innovation platform and life science accelerator and its member firms are notching up efforts to nurture Korean bioventures through the country’s first coalition fund.
Positive data from the PSMAddition trial potentially doubles the number of prostate cancer patients eligible for treatment with the Swiss major’s big-selling radioligand therapy but a discussant at ESMO was not convinced by the study.
Data from the EV-303/KEYNOTE-905 trial show the potential for the combination of Astellas/Pfizer’s ADC and Merck’s PD1 blocker to redefine standard of care.
The vocal shareholder tells Scrip that other investors have reached out supporting its push for a sale of the vaccine maker.
Chief medical officer Eliav Barr and EyeBio chief scientific officer Tony Adamis talk to Scrip about progress in eye diseases post Merck’s EyeBio acquisition.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
Yuhan's R&D president talks to Scrip about the leading Korean pharma firm’s open innovation strategy with Korean bioventures, as well as other strategies crucial for the company to transform into a major global player.
Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
CEO Renée Aguiar-Lucander tells Scrip that the Swedish team is well-equipped to take its desensitisation treatment for the adult kidney transplant to market in the US.
The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.
Fabrice Chouraqui is full of praise for the ‘amazing platform for growth’ established by predecessor Sijmen de Vries, which has left the Dutch firm poised to reap the rewards of its self-financing model.
Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.
The collaboration continues a hot streak for deals in the molecular glue degrader space and adds to Novartis’s recent string of acquisitions and licensing deals.
Charl van Zyl tells Scrip that pipeline is the priority as the company discontinues commercial operations in 27 markets.
The US FDA approved the novel drug-device system for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.
OMass Therapeutics has signed its debut licensing deal with Roche’s Genentech unit. Its CEO Rosamond Deegan talked to Scrip about what drew Roche’s interest to the preclinical IBD program, the company’s lead assets and the potential for other deals.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.